Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
121 hedge funds and large institutions have $401M invested in Kezar Life Sciences in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 55 increasing their positions, 39 reducing their positions, and 19 closing their positions.
5,426% more call options, than puts
Call options by funds: $1.49M | Put options by funds: $27K
41% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 39
0.85% less ownership
Funds ownership: 84.17% → 83.32% (-0.85%)
8% less funds holding
Funds holding: 132 → 121 (-11)
19% less capital invested
Capital invested by funds: $495M → $401M (-$94.4M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
53% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$20.9M |
| 2 |
DM
Deerfield Management
New York
|
+$10.6M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$10.1M |
| 4 |
State Street
Boston,
Massachusetts
|
+$5.31M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$4.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$20.3M |
| 2 |
HM
HealthCor Management
New York
|
-$13.8M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$8.18M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$5M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$4.79M |
KZR Hedge Fund Activity: Q4 2022 in Review
121 of the 6,239 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q4 2022, worth a combined $401M — down 19% from $495M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of KZR and 9 opened new positions — a net loss of 10 holders — while 39 trimmed existing stakes and 55 added.
The largest buyer was OrbiMed, adding an estimated $20.9M. The largest seller was Victory Capital Management, exiting entirely with an estimated $20.3M sold.
- 121 institutional investors held Kezar Life Sciences (KZR) as of Q4 2022, down from 132 in Q3 2022.
- Funds reported $401M of Kezar Life Sciences stock for Q4 2022, down 19% quarter-over-quarter.
- 9 funds opened new Kezar Life Sciences positions in Q4 2022 and 19 closed out, a net change of -10 holders.
- The largest Kezar Life Sciences buyer in Q4 2022 was OrbiMed, an estimated $20.9M added.
- The largest Kezar Life Sciences seller in Q4 2022 was Victory Capital Management, an estimated $20.3M sold.
Based on aggregated 13F filings for Q4 2022.